Fan Xiaozhou, Johnson Barbara H, Johnston Stephen S, Elangovanraaj Nivesh, Coplan Paul, Khanna Rahul
Medical Device Epidemiology and Real World Data Sciences, Johnson & Johnson, New Brunswick, NJ, USA.
Mu Sigma Inc, Bangalore, India.
Int J Gen Med. 2021 Jan 25;14:267-271. doi: 10.2147/IJGM.S290118. eCollection 2021.
We sought to examine the trend (April-July) in the treatment patterns among hospitalized COVID-19 patients using the Premier Healthcare Database (PHD). In the analysis, we identified 53,264 patients from 302 hospitalsthat continuously provided inpatient data from April 1, 2020 to July 31, 2020 to the PHD, a nationwide, population-based multihospital research database in the US. We used generalized estimating equations (GEE) models to assess changes in the proportion of therapies used during the study period. After adjusting for patient and provider factors, a decline in hydroxychloroquine and an increase in azithromycin and dexamethasone were observed among COVID-19 patients during the 4-month study period.
我们试图利用Premier医疗数据库（PHD）研究住院COVID-19患者治疗模式的趋势（4月至7月）。在分析中，我们从302家医院中识别出53264名患者，这些医院在2020年4月1日至2020年7月31日期间持续向PHD提供住院患者数据，PHD是美国一个全国性的、基于人群的多医院研究数据库。我们使用广义估计方程（GEE）模型来评估研究期间所用治疗方法比例的变化。在对患者和医疗服务提供者因素进行调整后，在4个月的研究期间，COVID-19患者中羟氯喹的使用比例下降，阿奇霉素和地塞米松的使用比例上升。
